Camargo Invests in High-Level IT System To Increase Accessibility and Preserve Client Data
Camargo Pharmaceutical Services recently completed an extensive IT system update
Camargo Pharmaceutical Services
recently completed an extensive IT system update to offer its clients improved data availability, security, storage and redundancy. The new system is an important investment to Camargo’s infrastructure, allowing the full-service development partner to add value for its clients.
With these improvements, Camargo provides each of its national and international clients with an individual website including large-scale data storage availability, document management with version control, a superior level of security with minimal interruptions and 24/7 rapid access. The system also includes data retention and preservation for at least 20 years — exceeding the FDA’s and global regulatory agencies’ minimum data preservation requirements.
“Implementing enhanced data access and storage capacity are examples of the strides Camargo is making to broaden our service line, support our clients from concept through commercialization and grow our client base internationally,” said Jim Beach, chief operating officer for Camargo. “Data and its preservation are the lifeblood of product development programs and this new system supports our critical role as stewards of our clients’ data.”
To learn more about Camargo’s service offerings, visit
camargopharma.com
.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.
